VTP 1100 / Barinthus Bio - LARVOL DELTA

Vaccitech Reports Full-Year 2022 Financial Results and an Update on Corporate Developments (GlobeNewswire) - "In 2023, the Company expects to: Announce the dosing of the first patient in PCA001, a Phase 1/2 clinical trial of VTP-850 designed to evaluate the safety, PSA response, and immunogenicity of the VTP-850 heterologous immunotherapeutic as monotherapy in men with rising PSA after definitive local therapy for their disease (i.e., biochemical recurrence)....Submit IND applications for its two lead SNAPvax candidates, VTP-1000 for the treatment of celiac disease and VTP-1100 for the treatment of HPV-associated cancers."

IND • P1/2 data • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Vaccitech Reports Third Quarter 2022 Financial Results and Recent Corporate Developments (GlobeNewswire) - "Upcoming Milestones - In the first quarter of 2023, the Company:...Expects to have FPFV for VTP-850 in our prostate cancer program; In 2023, the Company expects to...Have FPFV for VTP-1100 in our HPV cancer program."

Trial status • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Publication in Cell Shows That Vaccitech’s SNAPvax Has the Potential to Treat Cancer by Reversing Suppressive Tumor Microenvironment with Novel “Vax-Innate” Paradigm (GlobeNewswire) - "Vaccitech plc...announced the publication of research in preclinical animal models demonstrating the potential of Vaccitech’s SNAPvax for use in a novel paradigm for cancer treatment referred to as 'VAX-INNATE'....The research evaluated SNAPvax co-delivering tumor antigens and a powerful Toll-like receptor (TLR)-7/8 adjuvant by two different routes (IV or subcutaneous) in tumor-bearing mice. While SNAPvax primed and expanded a high magnitude of antigen-specific T cells by both routes of administration, SNAPvax administered by the IV route induced systemic Type I interferon that markedly reduced the number of immunosuppressive monocytes and macrophages in the TME leading to improved T cell mediated tumor regression....An Investigational New Drug (IND) application submission for SNAPvax candidate (VTP-1100) targeting human papilloma virus (HPV) associated cancer is expected during the first half of 2023."

IND • Preclinical • Oncology • Solid Tumor

Vaccitech Reports Second Quarter 2022 Financial Results and Recent Corporate Developments (GlobeNewswire) - "Upcoming Milestones: (i) In the fourth quarter of 2022, the Company expects to initiate dosing in a Phase 1/2 clinical trial of VTP-850 in patients with prostate cancer; (ii) In 2023, the Company expects to submit Investigational New Drug (IND) applications for its two lead SNAPvax candidates, VTP-1000 for the treatment of celiac disease and VTP-1100 for the treatment of HPV-associated cancers."

IND • New P1/2 trial • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor